Clinical-grade varicella zoster virus-specific T cells produced for adoptive immunotherapy in hemopoietic stem cell transplant recipients

References

• Arvin AM, Gershon AA. Varicella-Zoster Virus: Virology and Clinical Management. Cambridge: Cambridge University Press; 2000.
   Google Scholar
• Sartori AMC. A review of the varicella vaccine in immunocompromised individuals. Int J Infect Dis. 2004;8:259–70.
   PubMed Web of Science ®Google Scholar
• Hill G, Chauvenet AR, Lovato J, McLean TW. Recent steroid therapy increases severity of varicella infections in children with acute lymphoblastic leukemia. Pediatrics. 2005;116: e525–9.
   PubMed Web of Science ®Google Scholar
• Aytaç S, Yalçin SS, Küçükbayrak O, Cet n M, Uçkan D. Dynamics in children and adolescents who experience varicella zoster virus infections after haematopoietic stem cell transplantation: a case-control study. Epidemiol Infect. 2011;139:1701–9.
   Google Scholar
• Erard V, Guthrie KA, Varley C, Heugel J, Wald A, Flowers MED, et al. One-year acyclovir prophylaxis for preventing varicella-zoster virus disease after hematopoietic cell transplantation: no evidence of rebound varicella-zoster virus disease after drug discontinuation. Blood. 2007;110: 3071–7.
   PubMed Web of Science ®Google Scholar
• Abendroth A, Kinchington PR, Slobedman B. Varicella zoster virus immune evasion strategies. Curr Top Microbiol Immunol. 2010;342:155–71.
   PubMed Web of Science ®Google Scholar
• Torigo S, Ihara T, Kamiya H. IL-12, IFN-gamma, and TNF-alpha released from mononuclear cells inhibit the spread of varicella-zoster virus at an early stage of varicella. Microbiol Immunol. 2000;44:1027–31.
   PubMed Web of Science ®Google Scholar
• Jenkins DE, Redman RL, Lam EM, Liu C, Lin I, Arvin AM. Interleukin (IL)-10, IL-12, and interferon-gamma production in primary and memory immune responses to varicella-zoster virus. J Infect Dis. 1998;178:940–8.
   Google Scholar
• Weinberg A, Levin MJ. VZV T cell-mediated immunity. Curr Top Microbiol Immunol. 2010;342:341–57.
   Google Scholar
• Patterson-Bartlett J, Levin M, Lang N, Schodel F, Vessey R, Weinberg A. Phenotypic and functional characterization of ex vivo T cell responses to the live attenuated herpes zoster vaccine. Vaccine. 2007;25:7087–93.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Cosyns M, Levin MJ, Hayward AR. Cytokine production in varicella zoster virus-stimulated limiting dilution lymphocyte cultures. Clin Exp Immunol. 1994;98:128–33.
   PubMedGoogle Scholar
• Good RA, Zak SJ. Disturbances in gamma globulin synthesis as experiments of nature. Pediatrics. 1956;18:109–49.
   PubMed Web of Science ®Google Scholar
• Gershon AA, Arvin AM, Shapiro E. Varicella vaccine. N Engl J Med. 2007;356:2648–9.
   Google Scholar
• Hata A, Asanuma H, Rinki M, Sharp M, Wong RM, Blume K, et al. Use of an inactivated varicella vaccine in recipients of hematopoietic-cell transplants. N Engl J Med. 2002;347:26–34.
   PubMed Web of Science ®Google Scholar
• Heslop HE, Slobod K, Pule M, Hale G, Rousseau A, Smith C, et al. Long term outcome of EBV specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood. 2010;115:925–35.
   PubMed Web of Science ®Google Scholar
• Leen AM, Christin A, Myers GD, Liu H, Cruz CR, Hanley PJ, et al. Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein–Barr virus infections after haploidentical and matched unrelated stem cell transplantation. Blood. 2009;114:4283–92.
   PubMed Web of Science ®Google Scholar
• Bollard CM, Kuehnle I, Leen AM, Rooney CM, Heslop HE. Adoptive immunotherapy for posttransplantation viral infections. Biol Blood Marrow Transplant. 2004;10:143–55.
   PubMed Web of Science ®Google Scholar
• Micklethwaite KP, Hansen A, Foster AE, Snape E, Antonenas V, Sartor M, et al. Ex-vivo expansion and prophylactic infusion of CMV-pp65 peptide specific cytotoxic T-lymphocytes following allogeneic haemopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2007;13:707–14.
   PubMed Web of Science ®Google Scholar
• Micklethwaite KP, Clancy L, Sandher U, Hansen A, Blyth E, Antonenas V, Prophylactic infusion of cytomegalovirus-specific cytotoxic T lymphocytes stimulated with Ad5f35pp65 gene-modified dendritic cells after allogeneic hemopoietic stem cell transplantation. Blood. 2008;112:3974–81.
   PubMed Web of Science ®Google Scholar
• Blyth E, Clancy L, Simms R, Gaundar S, O’Connell PJ, Micklethwaite K, et al. BK virus specific T cells for use in cellular therapy show specificity to multiple antigens and polyfunctional cytokine responses. Transplantation. 2011;92:1014–1084.
   Google Scholar
• Betts MR. Sensitive and viable identification of antigen-specific CD8 + T cells by a flow cytometric assay for degranulation. J Immunol Methods. 2003;281:65–78.
   PubMed Web of Science ®Google Scholar
• McIver CJ, Jacques CFH, Chow SSW, Munro SC, Scott GM, Roberts JA, et al. Development of multiplex PCRs for detection of common viral pathogens and agents of congenital infections. J Clin Microbiol. 2005;43:5102–10.
   PubMed Web of Science ®Google Scholar
• Gaundar SS, Blyth E, Clancy L, Simms RM, Ma CKK, Gottlieb DJ. In vitro generation of influenza-specific polyfunctional CD4 + T cells suitable for adoptive immunotherapy. Cytotherapy. 2011;14:182–93.
   Google Scholar
• Kato S, Yabe H, Yabe M, Kimura M, Ito M, Tsuchida F, et al. Studies on transfer of varicella-zoster-virus specific T-cell immunity from bone marrow donor to recipient. Blood. 1990;75:806–9.
   PubMedGoogle Scholar
• Leung AYH, Chow HCH, Kwok JSY, Lui CKH, Cheng VCC, Yuen K-Y, et al. Safety of vaccinating sibling donors with live-attenuated varicella zoster vaccine before hematopoietic stem cell transplantation. Bone Marrow Transplant. 2007;39:661–5.
   PubMed Web of Science ®Google Scholar
• Berger C, Turtle CJ, Jensen MC, Riddell SR. Adoptive transfer of virus-specific and tumor-specific T cell immunity. Curr Opin Immunol. 2009;21:224–32.
   Google Scholar
• Harari A, Vallelian F, Meylan PR, Pantaleo G. Functional heterogeneity of memory CD4 T cell responses in different conditions of antigen exposure and persistence. J Immunol. 2005;174:1037–45.
   PubMed Web of Science ®Google Scholar
• Arvin A, Sharp M, Smith S, Koropchak C, Diaz P, Kinchington P, Equivalent recognition of a varicella-zoster virus immediate early protein (IE62) and glycoprotein I by cytotoxic T lymphocytes of either CD4+ or CD8+ phenotype. J Immunol. 1991;146:257–64.
   PubMed Web of Science ®Google Scholar
• Tilton J. Changes in paracrine interleukin-2 requirement, CCR7 expression, frequency, and cytokine secretion of human immunodeficiency virus-specific CD4 + T cells are a consequence of antigen load. J Virol. 2007;81:2713–25.
   PubMed Web of Science ®Google Scholar
• Landmeier S, Altvater B, Pscherer S, Eing BR, Kuehn J, Rooney CM, et al. Gene-engineered varicella-zoster virus reactive CD4 + cytotoxic T cells exert tumor-specific effector function. Cancer Res. 2007;67:8335–43.
   Google Scholar
• Melzi ML, Sonzogni A, Comoli P, Stroppa P, Riva S, Altobelli M, et al. Specific autologous cytotoxic T lymphocytes for chronic varicella in a liver transplanted child. Pediatr Transplant. 2006;10:240–3.
   Google Scholar
• Amir AL, D’Orsogna LJA, Roelen DL, van Loenen MM, Hagedoorn RS, de Boer R, et al. Allo-HLA reactivity of virus-specific memory T cells is common. Blood. 2010;115: 3146–57.
   PubMed Web of Science ®Google Scholar
• Melenhorst JJ, Leen AM, Bollard CM, Quigley MF, Price DA, Rooney CM, et al. Allogeneic virus-specific T cells with HLA alloreactivity do not produce GVHD in human subjects. Blood. 2010;116:4700–2.
   PubMed Web of Science ®Google Scholar